title: [Biomarker docetaxel-based chemotherapy].
abstract: In the prostate-specific antigen (PSA) era, prostate cancer is detected at more local stages. Nevertheless, depending on e.g. the differentiation stage there is recurrent disease in 10-40% of the cases with the need of further treatment. Once hormonal therapy has been initiated the disease can progress to the castration resistant stage and the question of chemotherapy arises. At this stage PSA sensitivity decreases. Although there is a significant improvement in survival only about 50% of the patients benefit from chemotherapy. Recently several new drugs have or will soon be approved in the setting of castration-resistant prostate cancer (CRPCA). Several prognostic molecular markers have been investigated. In this review some objective important biomarkers, proteins and targets will be presented.
authors: Klinik für Urologie, Universitätsklinikum Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland, dpfister@ukaachen.de.
authors: D
authors: D
authors: Pfister
authors: A
authors: A
authors: Heidenreich
authors: D
authors: D
authors: Porres
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D000077143:Docetaxel; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D015995:Prevalence; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D043823:Taxoids; D000077143:Docetaxel
references: Clin Cancer Res. 2008 Oct 1;14(19):6302-9
references: 18829513
references: Asian J Androl. 2013 Jan;15(1):110-5
references: 23147466
references: Urol Oncol. 2012 Sep;30(5):607-13
references: 20888271
references: Urol Oncol. 2012 Jan-Feb;30(1):33-7
references: 20207556
references: Ann Oncol. 2005 Mar;16(3):481-8
references: 15718248
references: J Clin Oncol. 2002 Oct 1;20(19):3972-82
references: 12351594
references: J Clin Oncol. 1999 Mar;17(3):1061-70
references: 10071301
references: N Engl J Med. 2011 May 26;364(21):1995-2005
references: 21612468
references: J Clin Oncol. 2003 Apr 1;21(7):1232-7
references: 12663709
references: Clin Cancer Res. 2010 Jan 1;16(1):203-11
references: 20008841
references: N Engl J Med. 2004 Oct 7;351(15):1502-12
references: 15470213
references: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references: 18309951
references: BJU Int. 2012 Dec;110(11 Pt B):E461-8
references: 22520631
references: Cancer Res. 2010 Nov 15;70(22):9253-64
references: 21045157
references: Clin Cancer Res. 2006 May 1;12(9):2774-9
references: 16675570
references: N Engl J Med. 2012 Sep 27;367(13):1187-97
references: 22894553
references: Int J Oncol. 2000 Apr;16(4):739-44
references: 10717242
references: Br J Cancer. 2009 Sep 15;101(6):951-6
references: 19690549
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24
references: 17062688
references: Prostate. 2009 Dec 1;69(16):1802-7
references: 19676083
references: Anticancer Drugs. 2006 Sep;17(8):993-6
references: 16940810
references: Cancer. 2008 Jun;112(11):2377-83
references: 18428198
references: Mol Cancer Ther. 2005 Dec;4(12):2001-7
references: 16373715
references: N Engl J Med. 2004 Oct 7;351(15):1513-20
references: 15470214
references: J Clin Oncol. 2012 Feb 20;30(6):637-43
references: 22184395
references: Lancet. 2010 Oct 2;376(9747):1147-54
references: 20888992
references: Clin Cancer Res. 2008 Jul 15;14(14):4511-6
references: 18628466
references: J Clin Oncol. 2007 Sep 1;25(25):3965-70
references: 17761981